

17 June 2020

ASX ANNOUNCEMENT

EARLY TAVR ANIMAL STUDY COMMENCED

Anteris Technologies (ASX:AVR) implanted its proprietary DurAVR™ Transcatheter Heart Valve into the first three animals (pigs) as part of a transcatheter aortic valve replacement (TAVR) study.

This first feasibility study in pigs aims to confirm DurAVR™ valve deployment and fixation (anchoring) as well as providing insight into the valve's haemodynamic function. The study of nine animals is being conducted in Minneapolis, USA and is scheduled to be completed by 31 December 2020.

The three pigs were implanted with a 25mm valve via a catheter by a trans-apical approach. The Effective Orifice Areas (EOA) were 2.45cm² on initial readings, consistent with the positive results observed in patients surgically implanted in the first-in-human SAVR clinical study and in previous animal and laboratory studies of the DurAVR™ valve. The EOA, a measurement of haemodynamic function, is a significant indicator of valve function and performance.

Additionally, the study replicated the findings of the 3D single-piece DurAVR™ aortic valve as shown in the surgical aortic valve replacement (SAVR) animal study and, thus far, in the first-in-human SAVR clinical study of the DurAVR™ valve underway at the University Hospitals, Leuven in Belgium.

This early feasibility study is critical as we move toward the next phase of development. The lessons learned in this study will allow us to make refinements to the frame and delivery system for the DurAVR™ aortic valve, which ultimately will be applied to the device used in our planned US FDA submission for a human clinical trial in 2021.

“The DurAVR™ valve continues to deliver superior performance observed to date. This pre-clinical study provides encouraging data and, importantly, will inform our development program and product design fine tuning.” Anteris CEO & Managing Director, Wayne Paterson, said.

Anteris Technologies Ltd


Registered Office:

Suite 302, Level 3 Toowong Tower, 9 Sherwood Road, Toowong QLD 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: info@anteristech.com W: anteristech.com



About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.


Authorisation and Additional information

This announcement was authorised by Mr John Seaberg, Company Chairman.

For more information:

Ms Kyahn Williamson
WE Communications
E: WE-AUAnterisTech@we-worldwide.com
P: +61 401 018 828

www.anteristech.com
Twitter: @AnterisTech
Facebook: www.facebook.com/AnterisTech



For personal use only